Bharat Biotech seeks nod for section 2/3 trial of Covaxin as booster amongst youngsters

Bharat Biotech has sought permission from the Drugs Controller General of India (DCGI) to conduct a section 2/3 trial of its Covid-19 vaccine Covaxin as a booster shot amongst these aged between two and 18, reported PTI .

“The Hyderabad-based firm had on April 29 submitted an application to DCGI seeking permission to conduct phase 2/3 trial to evaluate the safety, reactogenicity and immunogenicity of Covaxin as a booster dose in healthy volunteers aged 2 to 18 years,” the information company quoted an individual within the know as saying. 

The research is more likely to be performed at six websites, together with AIIMS Delhi and Patna.

Covaxin is at present being given to everyone aged 15+ though it has obtained a nod from DCGI to be used within the age group of six to 18 years.

“Earlier authorized for kids 12-18 years of age, Covaxin has confirmed to be protected, well-tolerated, and immunogenic in paediatric topics in section II/III research in kids 2-18 years of age,” Bharat Biotech had earlier mentioned. 

Covid-19 vaccinations for minors in India had been began from 3 January onwards for these within the 15-18 age group.


The drive later expanded on 16 March to incorporate kids aged above 12.

Booster doses in India

Both Covaxin and Covishield are being administered as booster doses to all adults presently who’ve accomplished 9 months after the second dose.

India started administering precaution doses of vaccines to the healthcare and frontline employees and people aged 60 and above with comorbidities on 10 January this yr. 

The comorbidity clause was eliminated in March, making all individuals aged above 60 eligible for the precautionary dose of the Covid vaccine.

The authorities expanded the ambit of the precaution doses of Covid-19 vaccines and on 10 April started administering the jabs to all aged above 18 years at personal vaccination centres. 

The NTAGI is now mulling early administration of the precaution dose to these travelling overseas for training, employment, sporting occasions and enterprise commitments.

The advisory panel is deliberating on lowering the hole between the second dose of the Covid-19 vaccine and the precaution dose from the present 9 months to 6 months for all.

Subscribe to Mint Newsletters

* Enter a legitimate e-mail

* Thank you for subscribing to our e-newsletter.

Source link